Envision a world
where no patient
is left behind

Despite decades of progress including innovation in antibody-based medicines, many patients continue to suffer without good treatment options. Vast aspects of the mechanisms driving serious diseases remain untapped, whereas existing treatments can be either ineffective or toxic.

Attovia aims to change this.

By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Envision
a world
where no
patient is
left behind

Despite decades of research and clinic progress, including innovations in antibody-based medicines, many patients continue to suffer due to a lack of good treatment options. Vast aspects of the mechanisms driving their disease are often inaccessible to current therapeutics. When treatments do exist, they can be toxic.

Attovia aims to change this.

By utilizing our ATTOBODY® technology, we will develop medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We will bring treatments to patients where none exist and create best-in-class options where current solutions fall short.

We envision a world where no patient is left behind.

ATTOBODIES: positioning for cures

Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement.

The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches.

Illustration of an attobody, a next-gen nanobody, binding to an oncology or immune-mediated disease target protein using spatial positioning technology.
Illustration of an attobody, a next-gen nanobody, binding to an oncology or immune-mediated disease target protein using spatial positioning technology.

Interested in learning more or discussing partnering opportunities?

Interested in learning more or discussing partnering opportunities?

Leading the way to first-in-class therapeutics

We are a seasoned team of drug development leaders passionate about bringing new and improved medicines to patients.

Image of Tao Fu, Attovia CEO

Tao Fu, MBA, M.S.

Chief Executive Officer

Image of Hubert Chen, Attovia CMO

Hubert Chen, M.D., M.P.H.

Chief Medical Officer

Image of Zaneta Odrowaz, Attovia CBO

Zaneta Odrowaz, PhD

Chief Business Officer

Image of Dr. Petter Veiby, Attovia CSO

Petter Veiby, Ph.D.

Chief Scientific Officer

Image of Dr. Hanjun Zhan, Attovia CTO

Hangjun Zhan, Ph.D.

Chief Technology Officer

Image of David Bellovin, Ph.D. VP

David Bellovin, Ph.D.

VP, Discovery & Translational Biology

Image of Veit Schmelmer, Ph.D.

Veit Schmelmer, Ph.D.

VP, Project Management & Portfolio Strategy

Image of Tao Fu, Attovia CEO

Tao Fu, MBA, M.S.

Chief Executive Officer

Image of Hubert Chen, Attovia CMO

Hubert Chen, M.D., M.P.H.

Chief Medical Officer

Image of Zaneta Odrowaz, Attovia CBO

Zaneta Odrowaz, PhD

Chief Business Officer

Image of Dr. Petter Veiby, Attovia CSO

Petter Veiby, Ph.D.

Chief Scientific Officer

Image of Dr. Hanjun Zhan, Attovia CTO

Hangjun Zhan

Chief Technology Officer

Image of David Bellovin, Ph.D. VP

David Bellovin, Ph.D.

VP, Discovery & Translational Biology

Image of Veit Schmelmer, Ph.D.

Veit Schmelmer, Ph.D.

VP, Project Management & Portfolio Strategy

Image of team of scientists developing attobody therapeutics

Start making a difference!

At Attovia, we value integrity, learning, performance, innovation, and collaboration. We work together, celebrate our successes together, and strive to make Attovia a place where everyone can grow.

Want to join the Attovia team? Let’s talk.

Image of team of scientists developing attobody therapeutics

Start making a difference!

At Attovia, we value integrity, learning, performance, innovation, and collaboration. We work together, celebrate our successes together, and strive to make Attovia a place where everyone can grow.

Want to join the Attovia team? Let’s talk.